Dr. Jordan goes to DC: Father of tamoxifen joins Lombardi

Publication
Article
Oncology NEWS Today BlogOncology NEWS Today Blog Vol 18 No 5
Volume 18
Issue 5

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

Dr. Jordan will take up his post at the Washington, DC-based institutions in July. He will also occupy an endowed chair. Dr. Jordan currently serves as vice president and scientific director for the medical sciences at Fox Chase Cancer Center in Philadelphia, where he holds the Alfred G. Knudson Jr., MD, PhD, Chair in Cancer Research. Dr. Jordan is also an adjunct professor of cancer biology at the University of Pennsylvania and a visiting professor of molecular medicine at the University of Leeds in England.

To learn more about Dr. Jordan’s life and career in “Father of tamoxifen a Brit to the core,” May 2008, visit www.cancernetwork.com

Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
Related Content